Facts and Figures: An overview

SFS looks back on a successful year. It achieved solid organic growth of 5.9% in its core business and increased its profitability significantly to 14.4% (adjusted EBITA margin). Moreover, thanks to two acquisitions, SFS established a firm position in the growing medical device market. SFS expects sales to grow by 8–10% in the 2017 financial year.

SFS achieved solid organic growth of 5.9% in its core business in the 2016 financial year. All segments contributed to this growth. They maintained and expanded their market positions. Consolidated sales reached a record high of CHF 1,437 million. This represents an increase of 4.4% from the previous year. Currency movements had a positive effect of 0.9% on reported sales, and changes in the scope of consolidation added 1.5% to the reported sales growth. Sales were reduced by CHF 50 million (3.9%) due to the phase-out of the trading activities, a non-core activity within the Engineered Components segment.

Please find detailed information in the media release published on 10 March 2017.

Income statement

in CHF million 2016 ± Vj. 2015
Gross sales 1,436.5 4.4% 1,376.3
EBITDA
As a % of net sales
300.5
20.9
12.4% 267.4
19.5
EBITA
As a % of net sales
216.8
15.1
16.2% 186.6
13.6
EBITA adjusted
As a % of net sales
207.3
14.4
20.7% 171.7
12.5
Operating profit (EBIT)
As a % of net sales
155.1
10.8
20.2% 129.1
9.4
Net income
As a % of net sales
122.2
8.5
16.4% 105.0
7.7
Cash net income
As a % of net sales
172.1
12.0
13.9% 151.1
11.0

Download business year 2016

Download business year 2015

Download business year 2014

Download business year 2013

Corporate Communications

SFS Group AG
Claude Stadler
Rosenbergsaustrasse 8
CH-9435 Heerbrugg
T +41 71 727 51 51
F +41 71 727 51 03